Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial

BACKGROUND: A 12-week, double-blind, parallel, multi-center randomized controlled trial in 316 adult patients with major depressive disorder (MDD) was conducted to evaluate the effectiveness of pharmacogenetic (PGx) testing for drug therapy guidance. METHODS: Patients with a CGI-S ≥ 4 and requiring...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez, Víctor, Salavert, Ariana, Espadaler, Jordi, Tuson, Miquel, Saiz-Ruiz, Jerónimo, Sáez-Navarro, Cristina, Bobes, Julio, Baca-García, Enrique, Vieta, Eduard, Olivares, José M., Rodriguez-Jimenez, Roberto, Villagrán, José M., Gascón, Josep, Cañete-Crespillo, Josep, Solé, Montse, Saiz, Pilar A., Ibáñez, Ángela, de Diego-Adeliño, Javier, Menchón, José M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513031/
https://www.ncbi.nlm.nih.gov/pubmed/28705252
http://dx.doi.org/10.1186/s12888-017-1412-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513031/
https://www.ncbi.nlm.nih.gov/pubmed/28705252
http://dx.doi.org/10.1186/s12888-017-1412-1

Ejemplares similares